Journal of Applied Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 62: 429-437, 1987;
8750-7587/87 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuchimukai, T.
Right arrow Articles by Enhorning, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuchimukai, T.
Right arrow Articles by Enhorning, G.

Journal of Applied Physiology, Vol 62, Issue 2 429-437, Copyright © 1987 by American Physiological Society


ARTICLES

Artificial pulmonary surfactant inhibited by proteins

T. Fuchimukai, T. Fujiwara, A. Takahashi and G. Enhorning

With a pulsating bubble surfactometer we assessed the ability of various agents, fibrinogen, human serum, albumin, and a 55,000-dalton serum protein, to interfere with the surface activity of Surfactant TA. From a highest final protein concentration of 4 mg/ml the potential inhibitors were diluted down to 0.125 mg/ml in six steps, and each concentration was evaluated together with two final phospholipid concentrations, 6.25 and 1.25 mg/ml, of the surfactant preparation. The strongest inhibiting action was exerted by fibrinogen, followed by human serum and the 55,000-dalton serum protein; the weakest inhibitor was albumin. Bilirubin, when added in an amount of 1.73 mg/100 ml dissolved in human serum, significantly (P less than 0.001) augmented the inhibition over that exerted by human serum alone. Adsorption rate, as reflected in the mean value of surface tension 2 and 10 s after creation of a bubble, not pulsating, was seriously affected by each of the protein-containing inhibitors in concentrations exceeding 1 mg/ml. Surface tension was raised significantly when the pulsating bubble was at maximal and minimal size. The effect was dose dependent. At maximal size it showed no tendency to disappear during the 10-min recording, but at minimal bubble size the inhibition gradually diminished. We conclude that proteins present in the airways may seriously interfere with the activity of Surfactant TA.


This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Gunther, N. Lubke, M. Ermert, R. T. Schermuly, N. Weissmann, A. Breithecker, P. Markart, C. Ruppert, K. Quanz, L. Ermert, et al.
Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits
Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1358 - 1365.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. J. Ryan, D. M. McCoy, S. E. McGowan, R. G. Salome, and R. K. Mallampalli
Alveolar sphingolipids generated in response to TNF-alpha modifies surfactant biophysical activity
J Appl Physiol, January 1, 2003; 94(1): 253 - 258.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M Gupta, J M Hernandez-Juviel, A J Waring, and F J Walther
Function and inhibition sensitivity of the N-terminal segment of surfactant protein B (SP-B1-25) in preterm rabbits
Thorax, November 1, 2001; 56(11): 871 - 876.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. G. LAFFEY, M. TANAKA, D. ENGELBERTS, X. LUO, S. YUAN, A. KEITH TANSWELL, M. POST, T. LINDSAY, and B. P. KAVANAGH
Therapeutic Hypercapnia Reduces Pulmonary and Systemic Injury following In Vivo Lung Reperfusion
Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2287 - 2294.
[Abstract] [Full Text]


Home page
J. Appl. Physiol.Home page
S. M. Wright, P. M. Hockey, G. Enhorning, P. Strong, K. B. M. Reid, S. T. Holgate, R. Djukanovic, and A. D. Postle
Altered airway surfactant phospholipid composition and reduced lung function in asthma
J Appl Physiol, October 1, 2000; 89(4): 1283 - 1292.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
P. Rauprich, O. Moller, G. Walter, E. Herting, and B. Robertson
Influence of Modified Natural or Synthetic Surfactant Preparations on Growth of Bacteria Causing Infections in the Neonatal Period
Clin. Vaccine Immunol., September 1, 2000; 7(5): 817 - 822.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
E. L. Heeley, J. M. Hohlfeld, N. Krug, and A. D. Postle
Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma
Am J Physiol Lung Cell Mol Physiol, February 1, 2000; 278(2): L305 - L311.
[Abstract] [Full Text] [PDF]


Home page
Hum Exp ToxicolHome page
B Jugg, J Jenner, and P Rice
The effect of perfluoroisobutene and phosgene on rat lavage fluid surfactant phospholipids
Human and Experimental Toxicology, November 1, 1999; 18(11): 659 - 668.
[Abstract] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
N. N. JARJOUR and G. ENHORNING
Antigen-induced Airway Inflammation in Atopic Subjects Generates Dysfunction of Pulmonary Surfactant
Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 336 - 341.
[Abstract] [Full Text]


Home page
J. Appl. Physiol.Home page
T. Kobayashi, K. Ohta, K. Tashiro, K. Nishizuka, W.-M. Chen, S. Ohmura, and K. Yamamoto
Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract
J Appl Physiol, June 1, 1999; 86(6): 1778 - 1784.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. M. HOHLFELD, K. AHLF, G. ENHORNING, K. BALKE, V. J. ERPENBECK, J. PETSCHALLIES, H. G. HOYMANN, H. FABEL, and N. KRUG
Dysfunction of Pulmonary Surfactant in Asthmatics after Segmental Allergen Challenge
Am. J. Respir. Crit. Care Med., June 1, 1999; 159(6): 1803 - 1809.
[Abstract] [Full Text]


Home page
Am. J. Respir. Crit. Care Med.Home page
Z. WANG and R. H. NOTTER
Additivity of Protein and Nonprotein Inhibitors of Lung Surfactant Activity
Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 28 - 35.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
O. V. Lopatko, S. Orgeig, C. B. Daniels, and D. Palmer
Alterations in the surface properties of lung surfactant in the torpid marsupial Sminthopsis crassicaudata
J Appl Physiol, January 1, 1998; 84(1): 146 - 156.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
G. Grossmann, Y. Suzuki, B. Robertson, T. Kobayashi, P. Berggren, W.-Z. Li, G.-W. Song, and B. Sun
Pathophysiology of neonatal lung injury induced by monoclonal antibody to surfactant protein B
J Appl Physiol, June 1, 1997; 82(6): 2003 - 2010.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. H. van Blankenstein, C. J Slager, L. K. Soei, H Boersma, T. Stijnen, J.C.H Schuurbiers, R. Krams, B Lachmann, and P. D Verdouw
Cardiac depression after experimental air embolism in pigs: role of addition of a surface-active agent
Cardiovasc Res, June 1, 1997; 34(3): 473 - 482.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online